BACKGROUNDdiabetes is a serious health problem and a source of risk for numerous severe complications such as obesity and hypertension. Treatment of diabetes and its related diseases can be achieved by inhibiting key digestives enzymes-related to starch digestion secreted by pancreas.METHODSThe formulation omega-3 with fenugreek terpenenes was administrated to surviving diabetic rats. The inhibitory effects of this oil on rat pancreas α-amylase and maltase and plasma angiotensin-converting enzyme (ACE) were determined.RESULTSthe findings revealed that administration of formulation omega-3 with fenugreek terpenenes (Om3/terp) considerably inhibited key enzymes-related to diabetes such as α-amylase activity by 46 and 52% and maltase activity by 37 and 35% respectively in pancreas and plasma. Moreover, the findings revealed that this supplement helped protect the β-Cells of the rats from death and damage. Interestingly, the formulation Om3/terp modulated key enzyme related to hypertension such as ACE by 37% in plasma and kidney. Moreover administration of fenugreek essential oil to surviving diabetic rats improved starch and glucose oral tolerance additively. Furthermore, the Om3/terp also decreased significantly the glucose, triglyceride (TG) and total-cholesterol (TC) and LDL-cholesterol (LDL-C) rates in the plasma and liver of diabetic rats and increased the HDL-Cholesterol (HDL-Ch) level, which helped maintain the homeostasis of blood lipid.CONCLUSIONoverall, the findings of the current study indicate that this formulation Om3/terp exhibit attractive properties and can, therefore, be considered for future application in the development of anti-diabetic, anti-hypertensive and hypolipidemic foods.

01 Jun 2010·Journal of Pediatric SurgeryQ3 · MEDICINE

Endorectal pull-through for Hirschsprung's disease—a multicenter, long-term comparison of results: transanal vs transabdominal approach

Q3 · MEDICINE

Article

Author: Jennifer N. Chamberlain ; Matthew D. Neal ; Brian T. Craig ; Patrick A. Dillon ; Erin K. Tkach ; Jacob C. Langer ; Cornelius E.J. Sloots ; Nicholas A. Hamilton ; David J. Hackam ; Daniel H. Teitelbaum ; Aimee C. Pastor ; Lingling Zhang ; Anne C. Kim ; Nicolaas M.A. Bax

PURPOSEPrevious studies have reported decreased continence in patients undergoing transanal endorectal pull-through (TERP) for Hirschsprung's disease compared to the older transabdominal approach (TAA). To address this, we examined long-term stooling outcomes in a large, multicenter cohort of patients undergoing either TERP or TAA.METHODSData were collected from 5 large pediatric institutions. Patient families were surveyed using a stooling score system (0-40, best to worst total score). Inclusion criteria included patients older than 3 years and those who had more than 6 months of recovery after pull-through. Those with total colonic aganglionosis were excluded. Statistical analysis included univariate and multivariate linear regression (significance, P < .05).RESULTSTwo hundred eighty-one patients underwent TERP (192) or TAA (89). Interviews were completed in 149 (104 [52%] TERP vs 45 [52%] TAA). The TAA group had a significantly greater number of daily bowel movements for each respective postoperative year and experienced more early complications (3% vs 1% with >1 complication; P = .061) and late complications (19% vs 4% with >1 complication; P < .001). Although the TAA group had a higher mean enterocolitis score (3.3 +/- 0.4 vs 1.8 +/- 0.2; P < .001), this was not borne out by multivariate regression analysis (P = .276). Parental survey showed that there were no significant differences between procedures in mean total, continence, or stooling pattern scores.CONCLUSIONTransanal endorectal pull-through was associated with fewer complications and fewer episodes of enterocolitis. In contrast to prior studies, TERP patients did not have a higher rate of incontinence. These results support use of TERP as an excellent surgical approach for children with Hirschsprung's disease.

American Journal of Cancer Research

Long-term efficacy of transoral endoscopic plasma resection in the treatment of early glottic laryngeal cancer and analysis of prognostic factors

Article

Author: Huang, Xiujuan ; Li, Tingting ; Wang, Yuanyuan ; Guo, Guangming ; Xu, Jinfeng ; Xu, Weiwei ; Chen, Ping

This study aimed to evaluate the efficacy of transoral endoscopic plasma resection (TEPR) in treating early glottic laryngeal cancer (GLC) and identify prognostic factors. A retrospective analysis was conducted on the medical records of 212 patients with early GLC treated with TEPR between February 2015 and September 2018 at Dongying People's Hospital. Clinical characteristics, objective voice function changes, and clinical outcomes of the patients were analyzed. Meanwhile, Kaplan-Meier curve was plotted to assess the impact of TERP on 3- and 5-year survival in GLC patients. Additionally, univariate and multivariable logistic regression analyses were performed to assess prognostic factors for GLC recurrence, and Receiver Operating Characteristic (ROC) curves were generated to assess their predictive value for patients' prognosis. After surgery, Patients' Jitter (%), Shimmer (%) showed significant improvement from pre-surgery, in contrast to Harmonic noise ratio and maximum phonation time, which underwent a significant decrease. The study assessed success and recurrence rates over 3- and 5-year follow-up periods, revealing a disease control rate of 86.79%, with 3- and 5-year recurrence rates of 14.62% and 20.28%, respectively. Patients were categorized into favorable and unfavorable prognosis groups based on the 3-year recurrence. Univariate analysis identified significant risk factors for recurrence, including age, tumor-node-metastasis (TNM) stage, clinical stage, and cumulative anterior commissure involvement (P < 0.05). Further multivariate logistic regression confirmed the above indexes as independent risk factors impacting patient prognosis. In conclusion, TEPR effectively treats early GLC, though recurrence risk persists, with age, TNM stage, clinical stage, and anterior commissure involvement identified as prognostic risk factors, suggesting the need for targeted preventive measures in clinical practice.

100 Deals associated with TERP API (Nanology Labs)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nervous System Diseases	Preclinical	US	NanOlogy LLCStartup	-
Solid tumor	Preclinical	US	NanOlogy LLCStartup	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

TERP API (Nanology Labs)

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation